41 – 50 of 82
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis
(
- Contribution to journal › Article
-
Mark
The European Vasculitis Society 2016 Meeting Report
(
- Contribution to journal › Article
-
Mark
Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts
(
- Contribution to journal › Article
-
Mark
Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis
(
- Contribution to journal › Letter
- 2016
-
Mark
Rituximab for treatment of severe renal disease in ANCA associated vasculitis
(
- Contribution to journal › Article
-
Mark
ANCA-associated glomerulonephritis : Risk factors for renal relapse
(
- Contribution to journal › Article
- 2015
-
Mark
Alemtuzumab as Remission Induction Therapy in Behçet Disease: A 20-year Experience.
(
- Contribution to journal › Article
-
Mark
Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials
(
- Contribution to journal › Article
-
Mark
Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.
(
- Contribution to journal › Article
-
Mark
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
(
- Contribution to journal › Article